Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Min Su
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07247968CT.gov Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study | — | Recruiting | — | — | — |
NCT06644573CT.gov Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia | — | Not Yet Recruiting | — | — | — |
NCT03666494CT.gov Ketamine Co-induction for Patients With Major Depressive Disorder | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Propofol (this asset) | Min Su | Approved | BB · 65 |
| Brexpiprazole | Dr. Albert Kar-Kin Chung | P4 | A |
| Saredutant | Sanofi | P3 | BBB |
| Jnj-54135419 | Chinese PLA General Hospital | P4 | BBB |
| Escitalopram | Poznan University of Medical Sciences | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | VA Office of Research and Development | P4 | BBB |
| Lithium, Elemental | Rakitzi, Stavroula | P4 | BBB |
| VENLOR | Janssen Research & Development, LLC | P4 | BBB |
| Paroxetine | Brigham and Women's Hospital | P4 | BBB |
+42 more in the Depressive Disorder cohort
Other indications for Propofol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Headache Disorder | — | P4 | BBB · 73 |
| Morbid Obesity | — | P4 | BBB · 73 |
| Alzheimer Disease | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Propofol in Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/propofol-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →